Video

Dr. Landi on the Association Between Genetic Variance and Melanoma Risk

Author(s):

Maria Teresa Landi, MD, PhD

Maria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the association between genetic variance and melanoma risk.

Maria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the association between genetic variance and melanoma risk.

In a large, global, meta-analysis of Caucasian patients, the association between genetic variance and risk of melanoma was evaluated.

Related Videos
Matthew P. Deek, MD
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
Guru P. Sonpavde, MD
David Rimm, MD, PhD
Suneel Kamath, MD
Kathleen N. Moore, MD, MS
Shaji Kumar, MD
Janaki Neela Sharma, MD
Karine Tawagi, MD,
Vered Stearns, MD
Related Content
RP1 Plus Nivolumab in Advanced Melanoma
November 22nd 2024

Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

IMA203 in Melanoma
November 11th 2024

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors

Lung Cancer
November 11th 2024

E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors